July 18, 2008 -- CMOs step in when pharmaceutical companies opt to outsource their manufacturing process in order to improve efficiency and productivity. Usually, this step can prove vital in slashing the costs of small to medium-sized companies, especially those that focus on biological or biotechnological R & D. However, investing in CMOs is associated with several risks, according to pharmaceutical industry experts at the ChinaBio® Investor Forum 2008, held in Shanghai last week. More details...
